Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1977 Sep;36(3):341–346. doi: 10.1038/bjc.1977.198

A preliminary study of intravenous methanol extraction residue of BCG in treatment of advanced cancer.

E Robinson, A Bartal, J Honigman, Y Cohen
PMCID: PMC2025428  PMID: 336070

Abstract

Twenty-four patients with advanced cancer not reacting to conventional therapy were treated with 97 courses of i.v. MER (methanol extraction residue of BCG). MER was administered by i.v. infusion over a 4-h period, twice a week, in dosages varying from 0.05 mg to 1.25 mg. The skin reactivity to 5 recall antigens was evaluated in the patients. All patients except 4 were anergic. Twelve patients had no side-effects. Anergic patients had less side-effects than ergic patients. The side-effects recorded in the others were fever, chills, vomiting and tachycardia. The reaction subsided within 24 h after treatment and was tolerable for most patients. In 2 patients an objective improvement was observed. No changes in cutaneous reactivity, renal and hepatic functions were found. A significant increase in peripheral leucocyte count was noted in two patients and slight a increase in the remainder.

Full text

PDF
346

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin R. W., Pimm M. V. BGG immunotherapy of local subcutaneous growths and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer. 1973 Sep 15;12(2):420–427. doi: 10.1002/ijc.2910120213. [DOI] [PubMed] [Google Scholar]
  2. Band P. R., Jao-King C., Urtasun R. C., Haraphongse M. Phase I study of corynebacterium parvum in patients with solid tumors. Cancer Chemother Rep. 1975 Nov-Dec;59(6):1139–1145. [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer. N Engl J Med. 1974 Jun 27;290(26):1458–1469. doi: 10.1056/NEJM197406272902605. [DOI] [PubMed] [Google Scholar]
  4. Cheng V. S., Suit H. D., Wang C. C., Cummings C. Nonspecific immunotherapy by Corynebacterium parvum: phase I toxicity study in 12 patients with advanced cancer. Cancer. 1976 Apr;37(4):1687–1695. doi: 10.1002/1097-0142(197604)37:4<1687::aid-cncr2820370412>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  5. Fisher B., Rubin H., Sartiano G., Ennis L., Wolmark N. Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study. Cancer. 1976 Jul;38(1):119–130. doi: 10.1002/1097-0142(197607)38:1<119::aid-cncr2820380121>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  6. Mansell P. W. Letter: Reactions to BCG. JAMA. 1973 Dec 24;226(13):1570–1571. doi: 10.1001/jama.1973.03230130058031. [DOI] [PubMed] [Google Scholar]
  7. Moertel C. G., Ritts R. E., Jr, Schutt A. J., Hahn R. G. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer. Cancer Res. 1975 Nov;35(11 Pt 1):3075–3083. [PubMed] [Google Scholar]
  8. Muggleton P. W., Prince G. H., Hilton M. L. Effect of intravenous B.C.G. in guineapigs and pertinence to cancer immunotherapy in man. Lancet. 1975 Jun 21;1(7921):1353–1355. doi: 10.1016/s0140-6736(75)92261-8. [DOI] [PubMed] [Google Scholar]
  9. Robinson E., Bartal A., Cohen Y., Haasz R. A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients. Br J Cancer. 1975 Jul;32(1):1–4. doi: 10.1038/bjc.1975.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sparks F. C., Silverstein M. J., Hunt J. S., Haskell C. M., Pilch Y. H., Morton D. L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973 Oct 18;289(16):827–830. doi: 10.1056/NEJM197310182891603. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES